Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 720 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Mild Clear all
Completed Not applicable Interventional

Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2

NCT03933696
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
Interventions
Tailored Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

NCT00153010
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NS 2330 (Tesofensine)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 85 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
80
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 30, 2026, 2:13 AM EDT
Recruiting Phase 2 Interventional

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

NCT07512362
View directory record Official record
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Interventions
human Mesenchymal Stem Cells
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

Repetitive Transcranial Magnetic Stimulation for Dementia

NCT02621424
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment
Interventions
RTMS, sham
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 30, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADNI: Alzheimer's Disease Neuroimaging Initiative

NCT00106899
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Lumbar Puncture (LP)
Procedure
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

NCT03472664
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
low carbohydrate/high fat diet, low fat/high carbohydrate diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial

NCT02525198
View directory record Official record
Conditions
Mild Cognitive Impairment, Subjective Memory Impairment
Interventions
fatty acid/flavonoid blend, Placebo
Dietary Supplement
Lead sponsor
University of East Anglia
Other
Eligibility
55 Years and older
Enrollment
259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Sep 30, 2026, 2:13 AM EDT
Enrolling by invitation No phase listed Observational

Expanding Access to Cognitive Health Biomarker Testing at Home

NCT07594665
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD), Subjective Cognitive Decline (SCD), Cognitive Aging
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

NCT01969123
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 30, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

NCT03279523
View directory record Official record
Conditions
Alzheimer Disease, HIV
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

NCT01600859
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2609, Placebo for E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Sep 30, 2026, 2:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

NCT04937959
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 30, 2026, 2:13 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

NCT06548191
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
Interventions
Time-restricted eating
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Computer-Based Training for Mild Alzheimer's Disease

NCT00319891
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Computer-based Cognitive Training
Procedure
Lead sponsor
Posit Science Corporation
Industry
Eligibility
60 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

NCT03649724
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Placebo, Eligard 22.5Mg Suspension for Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 120 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boca Raton, Florida • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Terminated Not applicable Interventional

Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI

NCT01870518
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment, Dementia
Interventions
Bilateral GPi DBS, Bilateral STN DBS
Device
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 30, 2026, 2:13 AM EDT
Recruiting Not applicable Interventional

Pulsed Electromagnetic Field Treatment With Dementia Patients

NCT06862557
View directory record Official record
Conditions
Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Interventions
ECHS AD Device
Device
Lead sponsor
Herrick Medical LLC
Industry
Eligibility
50 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

NCT02783573
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Lanabecestat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Anti-Oxidant Treatment of Alzheimer's Disease

NCT00117403
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q, Placebo capsules, Placebo wafers
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Tucson, Arizona • Irvine, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Sep 30, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Rasagiline
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Sep 30, 2026, 2:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

NCT01561430
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Sep 30, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 30, 2026, 2:13 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Brain Health Champion Study

NCT03772977
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild, Subjective Cognitive Decline, At Risk for Cognitive Decline
Interventions
Brain Health Champion
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 79 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Sep 30, 2026, 2:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Microbiome in Aging of Gut and Brain

NCT07799402
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease (AD), Dementia
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 2:13 AM EDT